Overview

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Status:
RECRUITING
Trial end date:
2027-07-15
Target enrollment:
Participant gender:
Summary
This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Meghan Shea
Collaborator:
GlaxoSmithKline
Treatments:
dostarlimab